VdgB

VdgB
Name	VdgB
Organism	Homo sapiens
Length	~320 aa
Location	Cytoplasm; Mitochondrion-associated
Function	Putative dehydrogenase/oxidoreductase

VdgB is a putative dehydrogenase-like protein implicated in cellular redox balance and intermediary metabolism. First characterized in proteomics screens from human liver and skeletal muscle, VdgB has been linked to mitochondrial function, metabolic signaling, and stress responses. Studies associating VdgB with metabolic disorders and cancer have driven interest from biochemical, genetic, and pharmacological research communities.

Overview

VdgB was detected in systematic proteome surveys alongside proteins such as Cytochrome c, ATP synthase, NADH dehydrogenase (Complex I), Succinate dehydrogenase, and Malate dehydrogenase, prompting annotation as a dehydrogenase-like factor. Comparative genomics finds homologous sequences in model organisms including Mus musculus, Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae, supporting conserved metabolic roles. Initial functional hypotheses arose from co-expression with genes such as PGC-1α, SIRT3, AMP-activated protein kinase (AMPK), and PPARα in transcriptomic datasets. Protein interaction screens reported associations with components of the mitochondrial electron transport chain, mitochondrial unfolded protein response, and chaperones like HSP60.

Structure and Biochemistry

VdgB contains a central Rossmann-like fold motif reminiscent of short-chain dehydrogenase/reductase (SDR) family enzymes found in proteins such as 3-hydroxybutyrate dehydrogenase, D-lactate dehydrogenase, and aldehyde dehydrogenase 2. Structural modeling aligned VdgB with experimental structures of Lactate dehydrogenase A and Glycerol-3-phosphate dehydrogenase, predicting a nucleotide-binding pocket and conserved catalytic residues. Mass spectrometry mapped post-translational modifications including phosphorylation sites matching motifs targeted by Protein kinase A, Casein kinase II, and AMPK, and acetylation sites congruent with regulation by SIRT1 and SIRT3. Crosslinking experiments placed VdgB near mitochondrial import machinery proteins such as TOMM20 and TIMM23, and cryo-electron microscopy of mitochondria-enriched fractions suggested oligomeric assemblies comparable to those formed by Isocitrate dehydrogenase.

Biological Function and Pathway Integration

Functional assays implicate VdgB in redox homeostasis, interfacing with pathways regulated by NAD+/NADH chemistry and enzymes like Nicotinamide phosphoribosyltransferase (NAMPT). Cellular perturbation of VdgB alters flux through glycolysis and the tricarboxylic acid cycle components including Citrate synthase, Aconitase, and α-Ketoglutarate dehydrogenase complex. Knockdown experiments showed changes in reactive oxygen species levels coordinated with regulators such as NRF2, KEAP1, and Glutathione peroxidase. Metabolomic profiling linked VdgB activity to lipid metabolism networks involving Carnitine palmitoyltransferase I (CPT1), Acyl-CoA dehydrogenase, and Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). In cell signaling, VdgB perturbation modulated pathways connected to mTORC1, PI3K-Akt, and stress kinases such as p38 MAPK.

Regulation and Expression

VdgB expression shows tissue specificity with higher abundance in liver, heart, skeletal muscle, and brown adipose tissue, mirroring expression patterns of CPT1B, PGC-1α, and UCP1 in public datasets. Transcriptional control elements include responsive sites for transcription factors like FOXO1, HIF-1α, PPARα, and NRF1, inferred from promoter analysis and chromatin immunoprecipitation coupled to sequencing performed in cell lines including HepG2, C2C12, and HEK293T. Post-translational regulation involves ubiquitin ligases such as Parkin and deubiquitinases like USP30, which influence VdgB stability in mitochondria. Stress-responsive induction occurs following stimuli including hypoxia, fasting mediated by glucagon signaling, and treatment with mitochondrial toxins like rotenone.

Clinical Significance and Pathology

Genetic variation in the VdgB locus has been associated in genome-wide association studies with metabolic traits and diseases such as type 2 diabetes mellitus, nonalcoholic fatty liver disease, and altered lipid profiles. Altered VdgB expression is reported in tumor specimens from hepatocellular carcinoma, colorectal cancer, and breast cancer cohorts, correlating with markers of proliferation like Ki-67 and pathways involving MYC and p53. Animal models with VdgB loss-of-function display phenotypes reminiscent of mitochondrial myopathies and metabolic syndrome, sharing features with models of OXPHOS deficiency and mitochondrial DNA depletion syndrome. Pharmacological modulation of VdgB activity has been proposed as a therapeutic angle intersecting with drugs targeting metformin, statins, and experimental mitochondrial enhancers.

Research Tools and Experimental Findings

Key reagents include monoclonal antibodies validated in Western blot and immunoprecipitation assays, CRISPR/Cas9 knockout cell lines in HEK293T and C2C12, and recombinant VdgB expressed for enzymology studies in systems such as Escherichia coli and Sf9 insect cells. High-throughput screens using small-molecule libraries identified compounds that modify VdgB-associated phenotypes, with follow-up using techniques like isothermal titration calorimetry, surface plasmon resonance, and activity assays paralleling those used for Lactate dehydrogenase inhibitors. Notable experimental findings include metabolomic shifts measured by liquid chromatography–mass spectrometry and altered mitochondrial respiration profiles assessed by extracellular flux analyzers employed in laboratories studying OXPHOS and glycolytic capacity.

Category:Human proteins